vs
艾伯维（ABBV）与Telix Pharmaceuticals Ltd（TLX）财务数据对比。点击上方公司名可切换其他公司
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Telix Pharmaceuticals是一家全球临床阶段生物制药企业，专注于肿瘤领域靶向放射性药物的研发与商业化，核心管线覆盖前列腺癌、肾癌、神经内分泌癌的诊断显像剂与治疗药物，业务遍及北美、欧洲及亚太地区。
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
ABBV
TLX
| Q4 25 | $16.6B | — | ||
| Q3 25 | $15.8B | — | ||
| Q2 25 | $15.4B | — | ||
| Q1 25 | $13.3B | — | ||
| Q4 24 | $15.1B | — | ||
| Q3 24 | $14.5B | — | ||
| Q2 24 | $14.5B | — | ||
| Q1 24 | $12.3B | — |
净利润ABBVTLX
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | — | ||
| Q2 25 | $938.0M | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $-22.0M | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
毛利率ABBVTLX
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVTLX
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | -9.9% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 27.6% | — | ||
| Q1 24 | 22.7% | — |
净利率ABBVTLX
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 9.5% | — | ||
| Q1 24 | 11.1% | — |
每股收益（稀释后）ABBVTLX
| Q4 25 | $1.02 | — | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $0.52 | — | ||
| Q1 25 | $0.72 | — | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $0.88 | — | ||
| Q2 24 | $0.77 | — | ||
| Q1 24 | $0.77 | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
